Ceplene is administered for maintenance of first remission in patients with AML, the most common type of Leukemia in adults.
Del Mar Pharmaceuticals Plans Clinical Trials for GBM Treatment
DMP estimates that the market for treating GBM patients post front-line therapy exceeds US$200 million annually in North America.
